Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.3%

10 terminated/withdrawn out of 75 trials

Success Rate

72.2%

-14.3% vs industry average

Late-Stage Pipeline

8%

6 trials in Phase 3/4

Results Transparency

62%

16 of 26 completed trials have results

Key Signals

17 recruiting16 with results8 terminated

Enrollment Performance

Analytics

Phase 1
61(83.6%)
Phase 3
6(8.2%)
Phase 2
5(6.8%)
Early Phase 1
1(1.4%)
73Total
Phase 1(61)
Phase 3(6)
Phase 2(5)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (75)

Showing 20 of 75 trials
NCT07594236Phase 1Recruiting

Phase 1 Study of C.001 in Retinal Degeneration

Role: collaborator

NCT05135091Phase 3Recruiting

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

Role: collaborator

NCT04365101Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Role: collaborator

NCT02797470Phase 1Active Not Recruiting

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Role: collaborator

NCT06344026Phase 1Enrolling By Invitation

Phase 1/2a Study of ANPD001 in Parkinson Disease

Role: collaborator

NCT05353647Phase 2Active Not Recruiting

A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

Role: collaborator

NCT07135050Phase 1Recruiting

Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome

Role: collaborator

NCT03696030Phase 1Active Not Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Role: collaborator

NCT07451613Phase 1Recruiting

Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

Role: collaborator

NCT06557460Phase 2Recruiting

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Role: collaborator

NCT04119024Phase 1Recruiting

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Role: collaborator

NCT06186401Phase 1Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Role: collaborator

NCT06504381Phase 1Recruiting

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Role: collaborator

NCT03977662Phase 1Completed

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

Role: collaborator

NCT03249831Phase 1Active Not Recruiting

A Blood Stem Cell Transplant for Sickle Cell Disease

Role: collaborator

NCT03741127Phase 1Active Not Recruiting

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Role: collaborator

NCT03957954Phase 1Active Not Recruiting

Stem Cell Therapy for Limbal Stem Cell Deficiency

Role: collaborator

NCT04196413Phase 1Recruiting

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

Role: collaborator

NCT07106021Phase 1Recruiting

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

Role: collaborator

NCT04652908Phase 1Recruiting

Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial

Role: collaborator